ANZUP TheraP study (Lu-177 PSMA-617 vs. cabazitaxel): overall survival after 3 years follow-up

Описание к видео ANZUP TheraP study (Lu-177 PSMA-617 vs. cabazitaxel): overall survival after 3 years follow-up

Presented at ASCO 2022 Annual Meeting by Prof. Michael Hofman

Комментарии

Информация по комментариям в разработке